Metabolic syndrome biomarkers and early breast cancer in Saudi women: Evidence for the presence of a systemic stress response and/or a pre-existing metabolic syndrome-related neoplasia risk?

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Alokail, Majed S ^a,b   Al Daghri, Nasser ^a,b   Abdulkareem, Amal ^c   Draz, Hossam M ^a,d   Yakout, Sobhy M ^a   Alnaami, Abdullah M ^a   Sabico, Shaun ^a   Alenad, Amal M ^e   Chrousos, George P ^a,f  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d NATIONAL RESEARCH CENTRE   (Egypt)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adiponectin; Breast cancer; HDL; Leptin; Saudi women

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN II; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; PROTEIN BLOOD LEVEL; SAUDI ARABIA; STRESS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOKINES; ADULT; ANGIOTENSIN II; ARABS; BLOOD PRESSURE; BREAST NEOPLASMS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INSULIN; LOGISTIC MODELS; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; ODDS RATIO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SAUDI ARABIA; STRESS, PHYSIOLOGICAL; TRIGLYCERIDES; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873204219     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-54     Document Type: Article

References (44)

1. World Health Organization Obesity and overweight fact sheet. May 2012 http://www.who.int/mediacentre/factsheets/fs311/en/, World Health Organization.
2. Calle EE, Rodriquez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Eng J Med 2003, 348:1625-1638.
3. Macciò A, Madeddu C, Mantovani G. Adipose tissue as target organ in the treatment of hormone dependent breast cancer: new therapeutic perspectives. Obes Rev 2009, 10:660-670. 10.1111/j.1467-789X.2009.00592.x, 19460113.
4. Carmichael AR. Obesity and prognosis of breast cancer. Obes Rev 2006, 7:333-340. 10.1111/j.1467-789X.2006.00261.x, 17038127.
5. Dirat B, Bochet L, Escourrou G, Valet P, Muller C. Unraveling the obesity and breast cancer links: a role for cancer-associated adipocytes?. Endocr Dev 2010, 19:45-52.
6. American Cancer Society Breast cancer facts and figures 2005-2006 2006, Atlanta, GS: American Cancer Society Inc, American Cancer Society.
7. Krebs EE, Taylor BC, Cauley JA, Stone KL, Bowman PJ, Ensrud KE. Measures of adiposity and risk of breast cancer in older post-menopausal women. J Am Geriatr Soc 2006, 54:63-69. 10.1111/j.1532-5415.2005.00541.x, 16420199.
8. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007, 121:856-862. 10.1002/ijc.22717, 17397032.
9. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, Kaplan RC, Harris TG, Howard BV, Wylie-Rosett J, Burk RD, Strickler HD. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009, 101:48-60. 2639294, 19116382.
10. Oh SW, Park CY, Lee ES, Yoon YS, Lee ES, Park SS, Kim Y, Sung NJ, Yun YH, Lee KS, Kang HS, Kwon Y, Ro J. Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Res 2011, 13:R34. 10.1186/bcr2856, 3219197, 21450081.
11. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 2008, 114:63-70. 10.1080/13813450801954451, 18465360.
12. Agnoli C, Berrino F, Abagnato CA, Muti P, Panico S, Crosignani P, Krogh V. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: A nested case-control study. Nutr Metab Cardiovasc Dis 2010, 20:41-48. 10.1016/j.numecd.2009.02.006, 2819536, 19361966.
13. Xue F, Michels KB. Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J ClinNutr 2007, 86:s823-s835.
14. Korner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, Bullen J, Neuwirth A, Tseleni S, Mitsiades N, Kiess W, Mantzoros CS. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 2007, 92:1041-1048.
15. Fischer S, Hanefeld M, Haffner SM. Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetol 2002, 39:105-110. 10.1007/s005920200027, 12357293.
16. Haluzík M, Parízková J, Haluzík MM. Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol Res 2004, 53:123-129.
17. Han C, Zhang HT, Du L. Serum levels of leptin, insulin, and lipids in relation to breast cancer in China. Endocrine 2005, 26:19-24. 10.1385/ENDO:26:1:019, 15805581.
18. Tworoger SS, Eliassen AH, Kelesidis T. Plasma adiponectin con-centrations and risk of incident breast cancer. J Clin Endocrinol Metab 2007, 92:1510-1516. 10.1210/jc.2006-1975, 17213279.
19. Albuquerque KV, Price MR, Badley RA. Pre-treatment serum lev-els of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival. Eur J Surg Oncol 1995, 21:504-509. 10.1016/S0748-7983(95)96935-7, 7589594.
20. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999, 19:1427-1432.
21. Bozcuk H, Uslu G, Samur M. Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clini-cal outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine 2004, 27:58-65. 10.1016/j.cyto.2004.04.002, 15242694.
22. Rolland YM, Perry HM, Patrick P, Banks WA, Morley JE. Leptin and adiponectin levels in middle-aged postmenopausal women: associations with lifestyle habits, hormones, and inflammatory markers-a cross-sectional study. Metabolism 2006, 55:1630-1636. 10.1016/j.metabol.2006.07.026, 17142136.
23. Yuan G, Zhou L, Tang J. Serum CRP levels are equally elevated in newly diagnosed type 2 diabetes and impaired glucose tol-erance and related to adiponectin levels and insulin sensitivity. Diabetes Res Clin Pract 2006, 72:244-250. 10.1016/j.diabres.2005.10.025, 16377022.
24. Il'yasova D, Colbert LH, Harris TB. Circulating levels of inflam-matory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005, 14:2413-2418. 10.1158/1055-9965.EPI-05-0316, 16214925.
25. Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol 2009, 5:374-381. 10.1038/nrendo.2009.106, 19488073.
26. Yvan-Charvet L, Quignard-Boulange A. Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int 2011, 79:162-168. 10.1038/ki.2010.391, 20944545.
27. Muniyappa R, Yavuz S. Metabolic actions of angiotensin II and insulin: a microvascular endothelial balancing act. Mol Cell Endocrinol 2012, [Epub ahead of print].
28. Rodriguez-Ferreira S, Abdelkarim M, Dillenburg-Pilla P, Luissint AC, di-Tommaso A, Deshayes F, Pontes CL, Molina A, Cagnard N, Letourneur F, Morel M, Reis RI, Casarini DE, Terris B, Couraud PO, Costa-Neto CM, Di Benedetto M, Nahmias C. Angiotensin II facilitates breast cancer cell migration and metastasis. PLoS One 2012, 7:e35667. 10.1371/journal.pone.0035667, 3334979, 22536420.
29. Jafri H, Alsheikh-Ali AA, Karas RH. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol 2010, 55:2846-2854. 10.1016/j.jacc.2009.12.069, 20579542.
30. Kucharska-Newton AM, Rosamond WD, Mink PJ, Alberg AJ, Shahar E, Folsom AR. HDL-cholesterol and incidence of breast cancer in the ARIC cohort study. Ann Epidemiol 2008, 18:671-677. 10.1016/j.annepidem.2008.06.006, 2566531, 18794007.
31. Deshayes F, Nahmias C. Angiotensin II receptors: a new role in cancer?. Trends Endocrinol Metabol 2005, 16:293-299.
32. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 2010, 10:745-759.
33. Melvin JC, Seth D, Holmberg L, Garmo H, Hammar N, Jungner I, Walldius G, Lambe M, Wigertz A, Van Hemelrijck M. Lipid Profiles and Risk of Breast and Ovarian Cancer in the Swedish AMORIS Study. Cancer Epidemiol Biomarkers Prev 2012, [Epub ahead of print].
34. Dalamaga M, Karmaniolas K, Papadavid E, Pelekanos N, Sotiropoulos G, Lekka A. Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters. Menopause 2011, 11:1198-1204.
35. Michels KB, Terry KL, Willett WC. Longitudinal study on the role of body size in premenopausal breast cancer. Arch Intern Med 2006, 166:2395-2402. 10.1001/archinte.166.21.2395, 17130395.
36. Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer 2001, 92:720-729. 10.1002/1097-0142(20010815)92:4<720::AID-CNCR1375>3.0.CO;2-T, 11550140.
37. Alokail MS, Al-Daghri NM, Al-Attas O, Hussain T. Combined effects of obesity and type 2 diabetes contribute to increased breast cancer risk among premenopausal women. Cardiovasc Diabetol 2009, 8:33. 10.1186/1475-2840-8-33, 2706231, 19545451.
38. Muti P, Quattrin T, Grant BJ. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2002, 11:1361-1368.
39. Rapp K, Schroeder J, Klenk J. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 2006, 49:945-952. 10.1007/s00125-006-0207-6, 16557372.
40. Furberg AS, Veierød MB, Wilsgaard T, Bernstein L, Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst 2004, 96:1152-1160. 10.1093/jnci/djh216, 15292387.
41. Soler M, Chatenoud L, Negri E, Parazzini F, Franceschi S, la Vecchia C. Hypertension and hormone-related neoplasms in women. Hypertension 1999, 34:320-325. 10.1161/01.HYP.34.2.320, 10454461.
42. Peeters PH, van Noord PA, Hoes AW, Fracheboud J, Gimbrère CH, Grobbee DE. Hypertension and breast cancer risk in a 19-year follow-up study (the DOM cohort). Diagnostic investigation into mammarian cancer. J Hypertens 2000, 18:249-254. 10.1097/00004872-200018030-00002, 10726709.
43. Pichard C, Plu-Bureau G, Neves-eCastro M, Gompel A. Insulin resist-ance, obesity and breast cancer risk. Maturitas 2008, 60:19-30. 10.1016/j.maturitas.2008.03.002, 18485631.
44. Chong YM, Williams SL, Elkak A, Sharma AK, Mokbel K. Insulin-like growth factor 1 (IGF-1) and its receptor mRNA levels in breast cancer and adjacent non-neoplastic tissue. Anticancer Res 2006, 26:167-173.